Business Standard

Post solid Q1, Apollo Hospitals on track for all-round growth, say analysts

Shares of Apollo Hospitals Enterprise (AHEL) rose 2.92 per cent to Rs 6,711.95 per share on the BSE in Friday's early morning trade

Prathap Chandra Reddy, Founder and Chairman, Apollo Hospitals Group (Photo credit: Pratap Vinayagam)

Prathap Chandra Reddy, Founder and Chairman, Apollo Hospitals Group (Photo credit: Pratap Vinayagam)

Shivam Tyagi New Delhi

Listen to This Article

Shares of Apollo Hospitals Enterprise (AHEL) rose 2.92 per cent to Rs 6,711.95 per share on the BSE in Friday’s early morning trade. This came after analysts remain bullish on the healthcare service providers growth outlook post a staggering show in the April-June quarter of the financial year 2024-25 (Q1FY25).

The Q1 financial performance was in line with the street estimates, helped by reduced operational costs by the healthcare group. However, hospital margins were flat year on year at 23.6 per cent, analysts said in their review notes.

At the same time, the hospital chain’s marketing efforts coupled with insurance tie-ups led to an impressive 68 per cent bed occupancy in Q1. Addition of 1,500 beds in the next five quarters shall ensure sustained growth momentum, those at Nuvama Institutional Equities noted. 

Click here to connect with us on WhatsApp

 

The hospital business growth in Q1 was largely driven by higher volume of patients, while the group's arm Apollo Health & Lifestyle Limited (AHLL) continued to post healthy sales and profitability across diagnostics, primary and secondary care segments, analysts at Motilal Oswal said. 

The company’s online pharmacy business, Apollo 24/7 also grew 15 per cent Y-o-Y, however, its gross merchandise value remained muted at Rs 690 crore. 

Vital signs
Apollo Hospitals is focusing on refurbishing acquired hospitals, obtaining regulatory approvals for new projects, and optimising its online pharmacy business, Apollo 24/7 platform, analysts said. 

The hospital group is also planning to open new stores for its offline pharmacy business (Apollo Pharmacy),  with the healthcare provider guiding to open 500–550 new stores in FY25. The mangement anticipates that this is expected to drive a 20 per cent growth in the Apollo Pharmacy business.

Analysts at Nuvama are positive about the company's growth prospects, anticipating a 15 per cent compund annual groeth rate (CAGR) in hospital revenue and Ebitda over FY24–27.

Despite a 150 basis point impact on hospital margins in FY26 from expected expansion, they remain optimistic long-term. They retained a 'Buy' rating with a revised target price of Rs 7,500, up from Rs 7,065.

Analysts at Motilal Oswal, too, maintained their ‘Buy’ call on the stock with a target price of Rs 7,940 per share. They project a 21 per cent Ebitda CAGR and a 41 per cent earnings CAGR between FY 24-26.

The global brokerage firm HSBC also maintained ‘Buy’ on the company at a target price of Rs 7,215.

Q1 earnings show
AHEL reported a substantial 83 per cent increase in net profit for the first quarter of FY 2024-25, reaching Rs 305 crore, compared to Rs 167 crore in the same period last year.

The hospital chain's revenue also saw a rise, up 15 per cent to Rs 5,086 crore from Rs 4,418 crore. Additionally, consolidated Ebitda grew by 33 per cent year-on-year, totaling Rs 675 crore, reflecting strong operational performance.

At Friday's close; the stock of the company ended 2.55 per cent higher at Rs 6,687.55 per share on the BSE. By comparison, the BSE Sensex closed 1.68 per cent higher at 80,436.84 levels. 

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Aug 16 2024 | 12:07 PM IST

Explore News